Cover Image
市場調查報告書

心肌纖維症:開發中產品分析

Myocardial Fibrosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 350076
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
心肌纖維症:開發中產品分析 Myocardial Fibrosis - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 68 Pages
簡介

心肌纖維症是由於心臟纖維芽細胞不正常增生造成心臟瓣膜異常肥大的疾病。症狀有胸部疼痛,腹部的膨脹滿感,噁心,疲勞感等。

本報告提供全球心肌纖維症治療用的開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

心肌纖維症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

心肌纖維症:企業開發中的治療藥

心肌纖維症:大學/機關研究中的治療藥

心肌纖維症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

心肌纖維症:企業開發中的產品

心肌纖維症:大學/機關研究中的產品

心肌纖維症治療藥的開發企業

  • AstraZeneca Plc
  • BioLineRx, Ltd.
  • Digna Biotech, S.L.
  • Evotec AG
  • Galectin Therapeutics, Inc.
  • GTx, Inc.
  • MandalMed, Inc.
  • miRagen Therapeutics, Inc.
  • ProMetic Life Sciences Inc.
  • Virocan Therapeutics Private Limited

心肌纖維症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

心肌纖維症:最近的開發平台趨勢

心肌纖維症:暫停中的計劃

心肌纖維症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9407IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H1 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Myocardial Fibrosis - Overview
  • Myocardial Fibrosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Myocardial Fibrosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Myocardial Fibrosis - Companies Involved in Therapeutics Development
  • Daewoong Pharmaceutical Co Ltd
  • Evotec AG
  • Galectin Therapeutics Inc
  • GTx Inc
  • Invivosciences Inc
  • Lead Discovery Center GmbH
  • MandalMed Inc
  • Merck & Co Inc
  • miRagen Therapeutics Inc
  • TRACON Pharmaceuticals Inc
  • Myocardial Fibrosis - Drug Profiles
  • carotuximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Tissue Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DWN-10290 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GMCT-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GRMD-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GTx-878 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MRG-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NM-922 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SP-20102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPI-2049 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TRC-205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Myocardial Fibrosis - Dormant Projects
  • Myocardial Fibrosis - Product Development Milestones
  • Featured News & Press Releases
  • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Myocardial Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Myocardial Fibrosis - Pipeline by Evotec AG, H1 2017
  • Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2017
  • Myocardial Fibrosis - Pipeline by GTx Inc, H1 2017
  • Myocardial Fibrosis - Pipeline by Invivosciences Inc, H1 2017
  • Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Myocardial Fibrosis - Pipeline by MandalMed Inc, H1 2017
  • Myocardial Fibrosis - Pipeline by Merck & Co Inc, H1 2017
  • Myocardial Fibrosis - Pipeline by miRagen Therapeutics Inc, H1 2017
  • Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Myocardial Fibrosis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Myocardial Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top